Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

2.
3.

Longstanding Challenges in Lung Cancer: Are We Meeting Them?

Snee M, Hatton MQ.

Clin Oncol (R Coll Radiol). 2016 Nov;28(11):669-671. doi: 10.1016/j.clon.2016.08.003. Epub 2016 Aug 21. No abstract available.

PMID:
27555083
4.

Collaborative Control of Cell Cycle Progression by the RNA Exonuclease Dis3 and Ras Is Conserved Across Species.

Snee MJ, Wilson WC, Zhu Y, Chen SY, Wilson BA, Kseib C, O'Neal J, Mahajan N, Tomasson MH, Arur S, Skeath JB.

Genetics. 2016 Jun;203(2):749-62. doi: 10.1534/genetics.116.187930. Epub 2016 Mar 30.

PMID:
27029730
5.

Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention.

Bayman N, Ardron D, Ashcroft L, Baldwin DR, Booton R, Darlison L, Edwards JG, Lang-Lazdunski L, Lester JF, Peake M, Rintoul RC, Snee M, Taylor P, Lunt C, Faivre-Finn C.

BMJ Open. 2016 Jan 27;6(1):e010589. doi: 10.1136/bmjopen-2015-010589.

7.

Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicity.

Murray L, Karakaya E, Hinsley S, Naisbitt M, Lilley J, Snee M, Clarke K, Musunuru HB, Ramasamy S, Turner R, Franks K.

Br J Radiol. 2016;89(1058):20150628. doi: 10.1259/bjr.20150628.

8.

Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Soodgupta D, Zhou H, Beaino W, Lu L, Rettig M, Snee M, Skeath J, DiPersio JF, Akers WJ, Laforest R, Anderson CJ, Tomasson MH, Shokeen M.

J Nucl Med. 2016 Apr;57(4):640-5. doi: 10.2967/jnumed.115.164624. Epub 2016 Jan 7.

9.

Stereotactic Ablative Radiotherapy (SABR) in Patients with Medically Inoperable Peripheral Early Stage Lung Cancer: Outcomes for the First UK SABR Cohort.

Murray L, Ramasamy S, Lilley J, Snee M, Clarke K, Musunuru HB, Needham A, Turner R, Sangha V, Flatley M, Franks K.

Clin Oncol (R Coll Radiol). 2016 Jan;28(1):4-12. doi: 10.1016/j.clon.2015.09.007. Epub 2015 Oct 21.

PMID:
26474546
10.

Stereotactic ablative body radiotherapy for lung cancer.

Franks KN, Jain P, Snee MP.

Clin Oncol (R Coll Radiol). 2015 May;27(5):280-9. doi: 10.1016/j.clon.2015.01.006. Epub 2015 Mar 4.

PMID:
25746732
11.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators..

Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18.

PMID:
25701171
12.

Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned.

Faivre-Finn C, Snee M.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):487-9. doi: 10.1016/j.ijrobp.2014.05.044. Epub 2014 Sep 26. No abstract available.

PMID:
25304944
13.

SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.

Maguire J, Khan I, McMenemin R, O'Rourke N, McNee S, Kelly V, Peedell C, Snee M.

Eur J Cancer. 2014 Nov;50(17):2939-49. doi: 10.1016/j.ejca.2014.07.009. Epub 2014 Oct 7.

PMID:
25304298
14.

Occult nodal disease in patients with non-small-cell lung cancer who are suitable for stereotactic ablative body radiation.

Robson JM, Vaidyanathan S, Cheyne L, Snee M, Franks K, Callister ME.

Clin Lung Cancer. 2014 Nov;15(6):466-9. doi: 10.1016/j.cllc.2014.07.006. Epub 2014 Aug 15.

PMID:
25220208
15.

Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing.

Snee M.

Clin Oncol (R Coll Radiol). 2014 Aug;26(8):468-72. doi: 10.1016/j.clon.2014.05.004. Epub 2014 Jun 6. Review.

PMID:
24909702
16.

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Butts C, Socinski MA, Mitchell PL, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Ciuleanu TE, Bosquée L, Trigo JM, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Pereira JR, Eberhardt WE, Helwig C, Schröder A, Shepherd FA; START trial team..

Lancet Oncol. 2014 Jan;15(1):59-68. doi: 10.1016/S1470-2045(13)70510-2. Epub 2013 Dec 9.

PMID:
24331154
17.

Heparin prophylaxis has no benefit in medical patients.

Snee M.

BMJ. 2012 Jul 31;345:e4940. doi: 10.1136/bmj.e4940. No abstract available.

PMID:
22851581
18.

Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer.

Price A, Yellowlees A, Keerie C, Russell S, Faivre-Finn C, Gilligan D, Snee M, Skailes G, Hatton M, Erridge S, Mohammed N.

Lung Cancer. 2012 Sep;77(3):532-6. doi: 10.1016/j.lungcan.2012.05.089. Epub 2012 Jun 4.

PMID:
22672970
19.

Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, Snee M, O'Brien M, Thomas G, Senan S, O'Byrne K, Kilburn LS, Spicer J, Landau D, Edwards J, Coombes G, Darlison L, Peto J; MARS trialists..

Lancet Oncol. 2011 Aug;12(8):763-72. doi: 10.1016/S1470-2045(11)70149-8. Epub 2011 Jun 30.

20.

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

International Collaboration of Trialists.; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group).; European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group.; Australian Bladder Cancer Study Group.; National Cancer Institute of Canada Clinical Trials Group.; Finnbladder.; Norwegian Bladder Cancer Study Group.; Club Urologico Espanol de Tratamiento Oncologico Group., Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK.

J Clin Oncol. 2011 Jun 1;29(16):2171-7. doi: 10.1200/JCO.2010.32.3139. Epub 2011 Apr 18.

Supplemental Content

Loading ...
Support Center